CEO to Present Data Analysis of Colorectal Cancer Pilot Study of Approximately 1,000 Subjects
NAMUR, Belgium, Sept. 5, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the Aegis Capital 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at Wynn Hotel in Las Vegas, NV.
Mr. Reynolds will present on Thursday, September 11, 2014 at 9:00 a.m. PT. During his presentation, he will discuss top-line results from analysis of an initial representative 938-subject sample from VolitionRx's 4,800-subject retrospective colorectal cancer blood diagnostic pilot study at Hvidovre Hospital, Denmark. Mr. Reynolds will also outline VolitionRx's business milestones and growth strategy.
VolitionRx's NuQ® tests utilize the Company's proprietary Nucleosomics® platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer signals within the blood. As part of the Denmark trial, VolitionRx is analyzing samples from approximately 4,800 subjects with colorectal cancer, polyps or adenomas, benign bowel diseases or other malignancies, all of whom have undergone a colonoscopy. Under the trial design, VolitionRx has full access to all Danish national registries and databases. The trial is designed to evaluate the diagnostic accuracy of the NuQ® test for colorectal cancer.
Details of the presentation are as follows:
Thursday, September 11, 2014
9:00 a.m. PT
The Encore at Wynn Hotel in Las Vegas, Nevada
Investors attending the Conference who would like to schedule a 1-on-1 meeting with VolitionRx management during the conference may do so by contacting their Aegis Capital Corp. representative, or Lee Roth of The Ruth Group at email@example.com.
For those unable to attend, a live webcast of Mr. Reynolds' presentation will be available on the Company's website at www.volitionrx.com. Following his presentation, this webcast will be archived for 90 days.
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Kirsten Thomas, The Ruth Group
Telephone: +1 (646) 536-7014
Scott Powell, Investor Relations
Telephone: +1 (917) 721-9480
Lee Roth, The Ruth Group
Telephone: +1 (646) 536-7012
SOURCE VolitionRx Limited